DV
Dividend Vision

XERS — Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. (XERS)

Total return is -57.5% over the past 8.1 years, 277.2 points behind SPY at 219.7%. Its deepest 1-year drawdown was 46.6%.

This is a single-stock equity holding in Xeris Biopharma Holdings, a healthcare company, rather than a diversified ETF product. The holding does not currently offer distributions to shareholders, resulting in no yield or distribution frequency data. With no disclosed expense ratio or assets under management information available, this appears to be a direct equity position suitable primarily for investors seeking exposure to the specialty pharmaceutical sector rather than traditional income generation.

XERS key facts

Asset type
Stock
Asset class
Equity
Inception date
06/21/2018
Distribution frequency
None
Last close
$8.60
Market cap
$1,567,954,688
Average volume
1366200.0
Beta
0.852
Payout ratio
0.0
P/E ratio
115.8571
Forward P/E
99.0099
EPS
$-0.10